Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study.
用户cLCxSEj5otc4
2天前
25
10
已关闭
DOI:
文献链接:
其他信息:
2024 AACR摘要和poster

